T1	intervention 0 68	Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy
T2	eligibility 423 491	Patients with clinical stage II breast cancer (T2N0, T1N1, and T2N1)
T3	total-participants 870 881	Fifty-three
T4	intervention-participants 905 907	26
T5	intervention 908 933	preoperative chemotherapy
T6	control-participants 938 940	27
T7	control 941 967	postoperative chemotherapy
T8	outcome 1335 1372	local/regional or distant recurrences
T9	iv-bin-abs 1374 1375	9
T10	cv-bin-abs 1393 1395	11
T11	outcome 1443 1475	overall or disease-free survival
T12	outcome 1250 1288	use of breast-conserving local therapy
T14	outcome 974 1006	objective clinical response rate
T15	iv-bin-percent 1061 1064	80%
T16	outcome 1074 1107	pathologic complete response rate
T17	iv-bin-percent 1112 1115	20%
T13	outcome 1155 1217	overall incidence and number of axillary lymph node metastases
